






































Ileal Crohn’sDiseaseExhibits Similar Transmural Fibrosis
Irrespective of Phenotype
Helena Tavares de Sousa, MD1,2, Irene Gullo, MD, PhD3,4,5, Claudia Castelli, MD6, Cláudia Camila Dias, BSc, MSc, PhD7,8,
Florian Rieder, MD, PhD9,10, Fátima Carneiro, MD, PhD3,4,5 and Fernando Magro, MD, PhD11,12,13
INTRODUCTION: InCrohn’sdisease (CD), theassessmentof transmural inflammationand fibrosis is of utmost importance.This
study aimed to quantify these parameters in CD ileal specimens and correlate themwith disease progression.
METHODS: This is a retrospective unicentric study based on the analysis of archived specimens (n 5 103) of
primary ileal resection. Data were retrieved from a prospective national inflammatory bowel disease
registry. Two pathologists, blinded for CD phenotype and clinical indications for surgery, examined 3
sections per patient and graded inflammation and fibrosis, based on a histopathological score.
RESULTS: Penetrating (B3, n5 74) CD exhibited significantly higher inflammation in diseased areas, compared with
stricturing (B2,n529)disease (score3:96%vs76%,P50.005 in inflamedareas;78%vs55%,P50.019
inmost affectedareas). Thiswasalsoobserved for thecomparisonofB2CDwithB3CDwith (B3s,n554)and
without associated stricture (B3o,n520):B3s vsB2:81%vs55%,P50.033 inmost affectedareas;B3ovs
B2:100%vs76%,P50.006ininflamedareas;70%vs55%,P50.039inmostaffectedareas.Wecouldnot
showdifferences in fibrosis scoresbetween the subphenotypes.Postoperativenewpenetratingevents occurred
only in B3s (n5 6, 11%, P5 0.043) patients. The changing of biologic therapy after surgery correlated with
severe inflammation at the proximal ileal margin (55% changed vs 25% not changed, P5 0.035).
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DISCUSSION: In our cohort, fibrosis scores and fibromuscular changes were comparable, irrespective of CD
phenotype. Inflammation severity was themajor differentiator between penetrating and stricturing
disease.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A546; http://links.lww.com/CTG/A547; http://links.lww.com/CTG/A548; http://
links.lww.com/CTG/A549; http://links.lww.com/CTG/A550; http://links.lww.com/CTG/A551; http://links.lww.com/CTG/A552; http://links.lww.com/CTG/A553; http://
links.lww.com/CTG/A554; and http://links.lww.com/CTG/A555.
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INTRODUCTION
Transmural inflammation and submucosal fibrosis are important
hallmarks of Crohn’s disease (CD) (1). Intestinal fibrosis con-
cerns extracellular matrix accumulation and mesenchymal cell
expansion (2,3). In this process, inflammation is the main acti-
vator of mesenchymal cells and an essential factor to initiate
fibrogenesis. Still, once fibrosis is established, it may be self-
propagating (3,4). In the setting of CD, patients with in-
flammatory lesions are considered medical therapy-responsive,
while thosewithmore fibrotic lesionswill eventually need surgery
(4). Hence, despite all the available therapies targeting in-
flammation, intestinal fibrosis remains difficult to treat and pre-
vent (3,4).
Strictures are subdivided in fibrotic, inflammatory, and
mixed forms (5). Pure fibrotic or inflammatory strictures are
rare, with both components presenting overlapped histopa-
thology (3,6–10). In CD, transmural intestinal inflammation
can be assessed by cross-sectional imaging (2,11–16). On the
other hand, fibrosis cannot be measured by this technique nor
through biomarkers (16,17). Endoscopy or biopsy-based his-
tology (2,11) is not feasible as tissue remodeling occursmostly in
deeper layers (18). Thus, the extent and severity of fibrosis must
be evaluated by histopathological analysis of intestinal resection
specimens, resorting to several histopathological scoring sys-
tems (19,20).
The main objective of our work was to characterize and
quantify inflammation and fibrosis, in ileal CD resection speci-
mens, according to a CD transmural histopathological scoring
system. We also aimed to correlate inflammation and fibrosis
profiles with progressive disease.
METHODS
Patients and study design
The patients included in this retrospective, single-center study
were selected as depicted in Supplementary Figure (see Supple-
mentary Digital Content 1, http://links.lww.com/CTG/A546).
Patients were retrieved from the prospective database of the
Portuguese Group for the Study of Inflammatory Bowel Disease
(GEDII) (gediibasedados.med.up.pt), according to the following
inclusion criteria: (i) definite diagnosis of CD with stricturing
(B2) or penetrating (B3) phenotypes, according to Montreal
criteria (21); (ii) emergent or elective ileal resection, due to CD
complications, at São João University Hospital Center (CHUSJ),
Porto, Portugal; and (iii) minimum postoperative follow-up of 3
years, up to January 2018.
Patients fulfilling the inclusion criteria were crossed with the
digital archive of the CHUSJ Pathology Department, available
since January 1998. Because of an overrepresentation of B3
phenotype with associated ileal stricture, a portion of this group
was randomly (Excel’s random numbers tool) excluded, to have
more balanced subgroups.
Demographical, clinical, and surgical information was re-
trieved from the GEDII database up to September 2019. All
missing data or discrepancies were obtained from clinical files.
The first ileal resection was considered the index episode (e.g.,
index surgery). Medical therapy data were collected for the pe-
riods before and after the index surgery and after the first sub-
sequent surgery.
Progressive disease
Progressive disease was defined as the occurrence of at least one of
the postoperative outcomes described elsewhere (22). The period
from index surgery to the occurrence of each outcome was
recorded.
Histopathologic workout
Two pathologists (I.G. and C.C.), blinded for CD phenotype
and indications for surgery, retrieved the formalin-fixed and
paraffin-embedded (FFPE) blocks of the ileal resection surgical
specimens. The macroscopic report, the gross picture of the
specimen (when available), and the description of the location
and/or lesion represented in each block were retrieved from the
files of the Department of Pathology and evaluated jointly
by both pathologists. On the basis of macroscopic grounds,
3 sections were selected from each specimen (Figure 1): (i)
margin: proximal ileal margin; (ii) most affected: (a) narrowest
caliber area of the ileal stricture, for specimens only with
strictures; (b) most severely inflamed ileal area (irrespective of
having an associated stricture or not), involved by fistulas,
fissures, and/or deep ulcers (defined as penetrating beyond the
submucosa (23)); and (iii) inflamed: (a) area of ileal stricture
outside the narrowest caliber, for specimens only with stric-
tures; (b) area of ileum with inflammatory changes outside the
most inflamed area, for specimens bearing fistulas, fissures,
and/or deep ulcers. If the 3 regions were not present in the
macroscopic report/picture, or if the information about the
exact location of each FFPE block was missing, the cases were
excluded (see Supplementary Figure, Supplementary Digital
Content 1, http://links.lww.com/CTG/A546).Moreover, all the
layers of the ileal wall (mucosa, submucosa, muscularis propria,
and serosa) were to be adequately represented and oriented on
each slide.
After a pre-evaluation of the slides to confirm the adequacy of
the specimens for the study, the pathologists graded in-
flammation and fibrosis according to a previously described CD
transmural histopathological score (23) (Table 1). Final scores
were obtained by consensus. The evaluation of inflammation
variables was mostly based on the histopathological analysis of
hematoxylin and eosin–stained slides. Macroscopic report and
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pictures of the surgical specimens were considered for in-
formation on ulceration extent. Fibrosis variables were assessed
onhematoxylin and eosin– andMasson trichrome–stained slides;
grossing reports provided information on stricture diameter.
As the adopted score does not specify to which layer the term
“muscular hyperplasia .25%” stands for, the feature was con-
sidered to be present if found either in muscularis propria or in
muscularis mucosae (MM). However, in our study, MM expan-
sion included either true cellular hyperplasia of smooth muscle
cell and/or a fibrosis-splayed layer (24). The presence of smooth
muscle or adipose tissue in the submucosal layer was also eval-
uated. A schematic representation of the main fibromuscular
changes in ileal intestinal wall in CD is presented in the Supple-
mentary Figure (see Supplementary Digital Content 2, http://
links.lww.com/CTG/A547).
As the selected histopathological score does not include a
0 (zero) score for grading inflammation, cases with absence of
inflammation were signaled for descriptive purposes but ex-
cluded from correlation analyses.
Statistical considerations
Categorical variables were summarized through absolute (n) and rel-
ative (%) frequencies. Continuous variables were described asmean6
SD or median (interquartile range), minimum, and maximum. Hy-
potheses on the distribution of continuous variables were tested using
the t test and the nonparametric Mann-Whitney and Kruskal-Wallis
tests. Associations between categorical and continuous variables were
tested through x2 and Spearman correlation tests, respectively. For
multiple comparison, Bonferroni correction was applied. IBM SPSS
Statistics for Mac, Version 24.0 (IBM, Armonk, NY) was used to
perform statistical analyses, adopting a 5% significance level.
Ethical considerations
Our studywas exempt of patients’ informed consent because of its
retrospective nature based on archived pathological material.
However, all patients gave consent for the collection of data from
the GEDII database, which was endorsed by the Portuguese Data
Table 1. Crohn’s disease transmural histopathological score (23)
Score Grade Features Score
Inflammation Mild Aphthous ulcers affected surface
,50%; cryptitis ,50%; inflammation
limited to mucosa
1
Moderate Large, superficial ulcers (0.5–2 cm)
Ulcerated surface ,50%; affected
surface 50%–100%
Cryptitis .50%; crypt abscesses;
submucosal inflammation
2
Severe Deepa ulcers or ulcers.2 cm in size;
circumferential ulcers; deepa fissures;
transmural inflammation
3





Mild stricture (.15 mm) with
nondilated lumen
Submucosal fibrosis and muscular
hyperplasia .25%b with preserved
layers
1
Severe Massive transmural fibrosis;




bIncludes muscular propria hyperplasia.25%, muscularis mucosae
hyperplasia .25%, and/or splayed muscularis mucosae (without cellular
hyperplasia) .25%.
Figure 1. Schematic representation of anatomical locations of the 3 per-
protocol sections for histopathological study, obtained from formalin-fixed
and paraffin-embedded blocks of ileal resection surgical specimens
(panels a to c). 1—Proximal ileal margin; 2—most affected area; and
3—inflamed area. (a) Schematic surgical specimen with strictures. (b)
Schematic surgical specimen with fistulas, fissures, and/or deep ulcers
and stricture. (c) Schematic surgical specimen with fistulas, fissures, and/
or deep ulcers only. Abs—abscess; asterisks—superficial ulcers; arrow—
deep ulcer (beyond submucosa). 1Inflammation (1–3) and fibrosis (0–2)
scoring: Higher scores indicate more severe inflammation and fibrosis,
respectively (23).


















Transmural Fibrosis in Ileal Crohn’s Disease 3
Table 2. Demographic, clinical, and surgery-related variables, per phenotype
Demographical and clinical variables Total
Phenotype at end of follow-up
B2 (n 5 29, 28%) B3 (n5 74, 72%) P a
Gender, n (%) 0.390
Female 46 (45) 11 (38) 35 (47)
Male 57 (55) 18 (62) 39 (53)
Age at diagnosis, n (%) 0.021
A1: #16 yr old 11 (11) 1 (3) 10 (14)
A2: 17–40 yr old 70 (68) 17 (59) 53 (72)
A3: .40 yr old 22 (21) 11 (38) 11 (15)
Phenotype at diagnosis, n (%) ,0.001
B1: nonstricturing, nonpenetrating 10 (10) 1 (3) 9 (12)
B2: stricturing 37 (36) 28 (97) 9 (12)
B3: penetrating 56 (54) 0 (0) 56 (76)
CD localization, n (%) 0.002
L1 58 (56) 18 (62) 40 (54)
L11L4 8 (8) 6 (21) 2 (3)
L3 32 (31) 3 (10) 29 (39)
L31L4 5 (5) 2 (7) 3 (4)
Perianal disease, n (%) 25 (24) 5 (17) 20 (27) 0.324
Age at diagnosis, yr, mean (SD) 30 (12) 35 (13) 28 (10) 0.001b
Total follow-up, yr, median (P25–P75) 10 (7–12) 12 (7–14) 10 (7–12) 0.024c
Surgery-related variables
Motif for first ileal surgery, n (%) ,0.001
Fistula/abscess 66 (64) 0 (0) 66 (89)
Perforation 5 (5) 0 (0) 5 (7)
Obstruction 32 (31) 29 (100) 3 (4)
First ileal surgery, n (%) .0.999
Segmental enterectomy 7 (7) 2 (7) 5 (7)
Ileocecal resection 86 (83) 24 (83) 62 (84)
Right hemicolectomy 10 (10) 3 (10) 7 (9)
Motif of reoperation, n (%) 0.050
Abscess 3 (30) 0 (0) 3 (42)
Stricture (primary) 4 (40) 3 (100) 1 (14)
Stricture (anastomotic) 3 (30) 0 (0) 3 (43)
Preoperative therapy, n (%)
5-aminosalicylic acid 49 (48) 15 (52) 34 (46) 0.664
Steroids 70 (68) 23 (79) 47 (64) 0.122
Immunosuppressives 60 (58) 16 (55) 44 (60) 0.692
Anti-tumor necrosis factor alphad 27 (26) 6 (21) 21 (28) 0.468
Postoperative therapy, n (%)
5-aminosalicylic acid 31 (30) 11 (38) 20 (27) 0.278
Steroids 32 (31) 14 (48) 18 (24) 0.018
Immunosuppressives 90 (87) 27 (93) 63 (85) 0.342
Anti-tumor necrosis factor alphae 61 (59) 18 (62) 43 (58) 0.713
Other biologicsf 11 (11) 4 (14) 7 (10) 0.724
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Protection Committee, authorization number 2868/2013. The
study protocol conforms to the ethical guidelines of Declaration
of Helsinki and was approved by the CHUSJ Ethic Committee on
July 2018. Confidentiality of data was ensured.
RESULTS
Study population
From a total of 103 patients, 29 were diagnosed with B2 CD
(stricturing disease) and 74 with B3 CD (penetrating disease). In
the B3 subgroup, 54 patients had at least 1 associated stricture
(B3s), while 20 had not (B3o). At diagnosis, B2 patients were, on
average, older than B3 ones (mean age: 35 vs 28 years old, P 5
0.001; age over 40 years old: 38% in B2 vs 15% in B3, P5 0.021).
Regardless isolated ileal location predominating in both pheno-
types, B2 CD affected more frequently the ileojejunal area when
compared with B3CD (B2 21% vs B3 3%, P5 0.002). By contrast,
B3 CD involved more frequently the ileocolonic area, when
compared with B3 CD (B3 39% vs B2 21%, P5 0.002) (Table 2).
Surgery-related variables and disease outcomes
The most common indication for first ileal surgery was fistula/
abscess (64%); ileal resection was performed in 83% of patients. B2
patients were, on average, older at the moment of index surgery
(mean age: 40 vs 32 years old, P5 0.008) (Table 2). After surgery,
more B2 patients were treated with steroids than B3 ones (48% vs
24%, P 5 0.018), with no differences in the number of steroid
courses needed or time from surgery to the first course (Tables 2
and 3). The proportion of patients who started immunosuppres-
sives after surgerywas similar betweenphenotypes (41% inB2, 48%
in B3). However, these were started significantly earlier in B2 pa-
tients (median: 5.8 vs 0.5 years, P 5 0.028). Most patients (63%)
started (39%) or changed (24%) biologic therapy (BT) (Table 3).
Disease progression occurred in 75 (73%) patients, and 10 (10%)
patients were reoperated at least once during follow-up, after a
median period of 6.7 years (1.8–10.4). Postoperative stricturing
eventswere reported in23 (22%)patients. Time fromindex surgery
to each outcome, i.e., time-to-event analysis, is displayed through
Kaplan-Meier curves (see Supplementary Figure, Supplementary
Digital Content 3, http://links.lww.com/CTG/A548).
Histopathological scoring according to section location
Overall, 10 patients (10%) showed no signs of inflammation on
proximal ileal margins, and 74 (72%) showed a score of 3 in most
affected regions. Histopathological scoring person can be found
in Supplementary Table (see Supplementary Digital Content 4,
http://links.lww.com/CTG/A549).
When comparing proximal ilealmargins with inflamed areas, the
inflammation scores increased in 70 (68%) patients, while fibrosis
scores did not change (n5 65; 63%). Regarding inflamed and most
affected areas, both inflammation and fibrosis scores remained un-
changed (n5 100; 97% and n5 98; 95%, respectively). Histopath-
ological scoring variation according to section location can be seen in
Supplementary Table (see Supplementary Digital Content 5, http://
links.lww.com/CTG/A550). Our study also evaluated the correlation
between inflammation and fibrosis scores (see Supplementary Table,
Supplementary Digital Content 6, http://links.lww.com/CTG/A551),
which was weak and only in inflamed areas (r5 0.198, P5 0.045).
Histopathological scoring in B2 and B3 CD
B2 vs B3 phenotypes. Three (15%) B2 patients and 7 (10%) B3
patients had no signs of histological inflammation in proximal
ileal margins (data not shown). B3 patients had significantly
higher inflammation score than B2 patients in inflamed andmost
affected areas (score 3: inflamed: 96% vs 76%, P 5 0.005; most
affected: 78% vs 55%, P 5 0.019) (Figure 2a, 2b). This tendency
was also observed for the total score, in both regions (score 4–5:
inflamed: 93% vs 72%, P 5 0.008; most affected: 79% vs 55%,
P 5 0.043). In terms of fibrosis, no significant differences were
Table 2. (continued)
Demographical and clinical variables Total
Phenotype at end of follow-up
B2 (n 5 29, 28%) B3 (n5 74, 72%) P a
Post-re-operative therapy (n 5 10), n (%)
5-aminosalicylic acid 2 (20) 1 (33) 1 (14) .0.999
Immunosuppressives 7 (70) 3 (100) 4 (57) 0.475
Anti-tumor necrosis factor alphag 8 (80) 2 (67) 6 (86) .0.999
Other biologicsh 1 (10) 1 (33) 0 (0) 0.300
Age at index surgery, yr, mean (SD) 34 (13) 40 (15) 32 (11) 0.008b
Time from diagnosis to index surgery, yr,
median (P25–P75)
2.0 (0.5–6.0) 3.0 (1.0–6.0) 2.0 (0.5–6.0) 0.273c
Bold entries indicate significant P values (P, 0.05).
CD, Crohn’s disease; L1, terminal ileum; L11L4, terminal ileum 1 upper gastrointestinal tract; L3, ileum and colon; L31L4, ileocolonic 1 upper gastrointestinal tract.
ax2 test.
bt test for independent samples.
cMann-Whitney test.
dInfliximab (n 5 22) and adalimumab (n 5 2).
eInfliximab (n 5 51) and adalimumab (n5 10).
fVedolizumab (n5 7) and ustekinumab (n5 4).
gInfliximab (n 5 7) and adalimumab (n5 1).
hVedolizumab (n5 1).
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observed between the 2 phenotypes, in the 3 studied areas
(Table 4; Figure 2c,d).
B2 phenotype vs B3s and B3o subphenotypes. Three (15%) B2, 2
(10%) B3o, and 5 (9%) B3s patients did not present inflammation
in proximal ileal margins (data not shown). Results for in-
flammation, fibrosis, and total scores for the B2 phenotype and
B3o and B3s penetrating subphenotypes are listed in the Sup-
plementary Data (Table 5 and see Supplementary Figure, Sup-
plementary Digital Content 7, http://links.lww.com/CTG/A552).
When comparedwith B2 patients, B3s patients presented with
significantly higher inflammation score in most affected areas
(inflammation score 3: 81% vs 55%, P 5 0.033), whereas total
score was significantly higher in inflamed areas (total score 4–5:
Table 3. Postoperative outcomes variables, per phenotype
Total (n5 103) B2 (n5 29, 28%) B3 (n5 74, 72%) P a
Reoperation, n (%) 10 (10) 3 (10) 7 (10) .0.999a
Time from index to subsequent surgery, yr,
median (P25–P75)b
6.7 (1.8–10.4) 6.0 (1.2–7.5) 7.8 (2.0–11.5) 0.425c
Hospitalization, n (%) 30 (29) 10 (35) 20 (27) 0.454a
Time from index to subsequent
hospitalization, yr, median (P25–P75)b
2.0 (0.8–3.5) 7.8 (1.2–3.0) 2.0 (0.7–4.2) 0.947c
Steroids, n (%) 32 (31) 14 (48) 18 (24) 0.018a
No. of postoperative steroid courses,
median (min–max)
1 (1–2) 1 (1–4) 1 (1–2) 0.185c
Time from index surgery to first steroid
course, yr, median (P25–P75)b
2.5 (0.5–5.1) 3.5 (0.8–7.8) 2.3 (0.2–3.5) 0.171c
Immunosuppressive (IS), n (%)
Start IS, n (%) 40 (39) 12 (41) 28 (38) 0.740a
Time from index surgery to IS, yr,median
(P25–P75)b
1.0 (0.1–5.3) 5.8 (0.6–7.7) 0.5 (0.1–3.3) 0.028c
Change IS, n (%) 7 (7) 2 (7) 5 (7) .0.999a
Time from index surgery to change IS, yr,
median (P25–P75)b
3.6 (1.5–4.2) 4.3 (4.0–4.5) 2.0 (1.5–3.6) 0.121c
BT, n (%)
Start BT, n (%) 40 (39) 14 (48) 26 (35) 0.218a
Time from index surgery to BT, yr,
median (P25–P75)b
5.7 (2.1–8.5) 8.6 (1.5–12.0) 5.3 (2.5–7.5) 0.187c
Change BT, n (%) 25 (24) 7 (24) 18 (24) 0.984a
Time from index surgery to change BT,
yr, median (P25-P75)b
4.0 (2.4–8.7) 8.5 (4.0–13.2) 4 (1.5–7.6) 0.079c
New event, n (%)
Stricturing, n (%) 23 (22) 10 (35) 13 (18) 0.072a
Time from index surgery to new
stricturing, yr, median (P25–P75)b
3.0 (1.0–6.0) 4.2 (2.5–7.2) 2.2 (1.0–5.0) .0.999c
Penetrating, n (%) 6 (6) 0 (0) 6 (8) 0.181a
Time from index surgery to new
penetrating, yr, median (P25–P75)b
2.2 (0.6–3.5) — 2.2 (0.6–3.5) —
Perianal, n (%) 2 (2) 1 (3) 1 (1) .0.999a
Time from index surgery to new perianal,
yr, median (P25–P50)b
2.2 (2.0–2.5) 2.5 (2.5–2.5) 2.0 (2.0–2.0) .0.999a
Progressive disease, n (%) 75 (73) 23 (79) 52 (70) 0.354a
Bold entries indicate significant P values (P , 0.05).
BT, biologic therapy; IS, immunosuppressive.
ax2 test.
bTime from index surgery to each outcome is considered only for patients presenting the outcome.
cMann-Whitney test.
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94% vs 72%, P 5 0.024). Regarding fibrosis score, we could not
find differences between the 2 groups.
The comparison between B2 and B3o patients showed that
B3o patients had significantly higher inflammation scores in all
3 studied areas (score 3: proximal ilealmargins: 61% vs 19%,P5
0.015; inflamed areas: 100% vs 76%, P 5 0.006; most affected
areas: 70% vs 55%, P 5 0.039). There were no differences be-
tween the 2 groups, in terms of fibrosis and total score.
B3o patients presented significantly higher inflammation
score thanB3s patients at the proximal ilealmargins only (score 3:
61% vs 29%, P 5 0.044). Regarding fibrosis and total score, no
differences were found between the 2 subphenotypes, in all areas.
The study of the contribution of individual histological fea-
tures to all CD subphenotypes showed that transmural in-
flammation was significantly more frequent in proximal ileal
margins of B3o patients (59% B3o vs 26% B3s vs 17% B2, P 5
0.013), while MM splay .25% (Figure 2c) was significantly less
frequent in inflamed areas (80% B3o vs 98% B3s vs 93% B2, P5
0.020). No differences between subphenotypes were found for all
the other histological variables (see Supplementary Table, Sup-
plementary Digital Content 8, http://links.lww.com/CTG/A553,
which presents the association of all selected histological features
per CD (subphenotype). Also, we could not evidence differences
between the histopathological scores of patients with andwithout
submucosal adipose or smooth muscle tissue. The 2 histological
variables according to histopathological scoring and section
location can be found in the Supplementary Data (see Supple-
mentary Table, Supplementary Digital Content 9, http://links.
lww.com/CTG/A554).
Progressive disease outcomes
Severe inflammation at proximal ileal margins was associated
with postoperative change of BT (score 3: 55% changedBT vs 25%
not changed BT, P5 0.035). No differences were found between
histopathological scores for the other outcomes. Also, we could
not establish associations between histology and postoperative
outcomes (data not shown). Postoperative outcomes in the 3 CD
subphenotypes are depicted in Supplementary Table (see Sup-
plementary Digital Content 10, http://links.lww.com/CTG/
A555). New penetrating events, after the index surgery, occurred
exclusively in B3s patients (n 5 6, 11%, P 5 0.043).
DISCUSSION
In this study, we quantified and characterized inflammation and
fibromuscular changes in ileal CD resection specimens according
to a CD histopathological score. We confirmed pure fibrotic
disease may not exist as, in most patients, both components
overlapped on histopathology, irrespective of disease phenotype
(25,26). Importantly, our study evidenced that the major differ-
entiator between penetrating and stricturing disease was the de-
gree of inflammation. Patients with penetrating disease both with
(B3s) or without (B3o) associated stricture exhibited higher
Figure 2. Ileal resections from B2 patients (a, hematoxylin and eosin [H&E]) showed lesser inflammation when compared with B3 patients (b, H&E; large
superficial ulcer). Both specimens from B2 (c, Masson trichrome [MT]) and B3 (d, MT) patients showed prominent fibrosis. Granulomatous inflammation
with giant cell (a, asterisk and inset). Hyperplastic and splayed muscularis mucosae, dissected by fibrosis (c, asterisk and inset).
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inflammation scores in diseased areas than pure stricturing (B2)
patients, with no differences in fibrosis scores. Yet, when com-
paring penetrating subphenotypes, B3o patients showed a sig-
nificantly higher inflammation score at the proximal ileal margin
only.
Penetrating disease is believed to coexist with strictures (4). Fis-
tula formation may be guided by both intraluminal pressure and
transmural inflammation-induced changes (27). This hypothesis is
supported by the higher inflammation grades observed in B3s pa-
tients when compared with B2 patients and, although uncommon,
by new postoperative penetrating events occurring in B3s patients.
Regarding B2 phenotype, we found inflammation and fibrosis
overlap (3,6–10) in most patients without purely fibrotic stricture in
all studied areas. However, we found strictures without fibrosis in
inflamed areas (n 5 2 of 29 patients). These might correspond to
pure inflammatory strictures because inflammation seems to be
required to initiate fibrogenesis (3,4).
Overall, grade 1 fibrosis was more frequent than grade 2, dem-
onstrating the importance of submucosal fibrosis and muscular ex-
pansion not only in stricturing (1,28), but also in penetrating disease.
A deeper analysis evidenced that B3o patients presented MM splay
with significantly less frequency in inflamed areas. The absence of
differences in other fibromuscular variables between groups suggests
that these changes are important irrespective of phenotype.
The presence of adipose tissue in the submucosa could represent a
potential surrogate of adjacent nonresected creeping fat (29), which
was shown to correlate with chronic inflammation (30), muscle hy-
pertrophy, fibrosis, and strictures (31,32). In our study, adipose tissue
in the submucosawasmore frequent in cases of higher inflammation
(score 3) and of mild to moderate fibroses (score 1). However, no
differences were found between CD subphenotypes, which may be
due to the reduced number of patients in this subgroup.
Our secondary aim was to correlate histopathological profiles
with progressive disease. New penetrating events occurred ex-
clusively in B3s patients. Also, postoperative need of changing BT
correlated with severe inflammation at the proximal ileal margin
irrespective of CD phenotype. Although the literature shows that
microscopic inflammation in resection margins does not affect
recurrence rates (33,34), our study suggests that severe in-
flammation in this area may represent a red flag for nonresponse
to an ongoing biologic at the time of surgery. CD subphenotypes,
histopathological cores, or variables did not correlate with the
other postoperative outcomes. Although most patients (73%)
presented progressive disease, the 10-year reoperation rate (10%)
was lower than previously reported (33%–39%) (35–37). How-
ever, relevant methodological differences hinder direct compar-
isons as our study is based solely on B2 andB3 surgical specimens.
This study has some limitations. First, its retrospective and
single-center study design led to many case exclusions,
resulting in a small B2 patients’ group and somewhat un-
derpowered the study. To avoid potential statistical con-
straints, we used Bonferroni correction to preserve statistical
significance regardless of subgroup size. Second, the use of
archived FFPE blocks could decrease the reliability of the
histopathological analyses, which may be also affected by
sampling error in the choice of tissue location. To overcome
this limitation, we performed a double, independent, blinded
pathological assessment and resorted to a systematic in-
flammation and fibrosis grading based on a histopathological
score (23). Moreover, we choose 3 different sections per
specimen to mitigate sampling error and selection biases.
Third, although this score showed highmethodological quality
and adequate properties (20), it was not validated and no
validated scores exist for this purpose. Finally, the exclusion of
cases with no inflammation in the proximal ileal resection
margin could potentially introduce a bias in the analysis.
Table 4. Histopathological scoring per section in stricturing (B2)
and penetrating (B3) Crohn’s disease
B2, n (%) B3, n (%) P a
Margins
Inflammation 0.094
1–2 21 (81) 42 (64)
3 5 (19) 24 (36)
Fibrosis 0.233
0 3 (10) 15 (20)
1 26 (90) 59 (80)
2 0 (0) 0 (0)
Total score 0.061
#2 20 (69) 30 (43)
3 4 (14) 18 (26)
4–5 5 (17) 22 (31)
Inflamed
Inflammation 0.005
1–2 7 (24) 3 (4)
3 22 (76) 71 (96)
Fibrosis 0.521
0 2 (7) 2 (3)
1 22 (76) 53 (72)
2 5 (17) 19 (26)
Total score 0.008
#2 1 (4) 0 (0)
3 7 (24) 5 (7)
4–5 21 (72) 69 (93)
Most affected
Inflammation 0.019
1–2 13 (45) 16 (22)
3 16 (55) 58 (78)
Fibrosis 0.774
0 0 (0) 1 (1)
1 26 (90) 68 (92)
2 3 (10) 5 (7)
Total score 0.043
#2 5 (17) 4 (5)
3 8 (28) 12 (16)
4–5 16 (55) 58 (79)
Inflammation (1–3) and fibrosis (0–2) scoring: Higher scores indicate more
severe inflammation and fibrosis, respectively (23).
Bold entries indicate significant P values (P , 0.05).
ax2 test.


















Tavares de Sousa et al.8
However, this was not the case because the subgroup analyses
including these 10 cases showed results consistent with those
presented herein with no difference between phenotypes.
The strengths of this study rely on the large number of included
patients and on the careful and well-defined histopathological
exercise, designed to obviate the above-mentioned limitations.
Table 5. Histopathological scoring per section and Crohn’s disease phenotype: stricturing (B2) vs penetrating without associated stricture
(B3o) vs penetrating with associated stricture (B3s)
B2 (n5 29), n (%) B3s (n 5 54), n (%) B3o (n5 20), n (%) P a P b P c
Margins
Inflammationd .0.999 0.015 0.044
1–2 21 (81) 35 (71) 7 (39)
3 5 (19) 14 (29) 11 (61)
Fibrosis 0.303 .0.999 0.645
0 3 (10) 13 (24) 2 (10)
1 26 (90) 41 (76) 18 (90)
Total scored 0.627 0.081 0.792
#2 17 (65) 22 (50) 5 (28)
3 4 (15) 15 (28) 3 (17)
4–5 5 (19) 12 (22) 10 (56)
Inflamed
Inflammation 0.067 0.006 .0.999
1–2 7 (24) 3 (6) 0 (0)
3 22 (76) 51 (94) 20 (100)
Fibrosis 0.234 .0.999 0.108
0 2 (7) 0 (0) 2 (10)
1 22 (76) 38 (70) 15 (75)
2 5 (17) 16 (30) 3 (15)
Total score 0.024 .0.999 .0.999
#2 1 (4) 0 (0) 0 (0)
3 7 (24) 3 (6) 2 (10)
4–5 21 (72) 51 (94) 18 (90)
Most affected
Inflammation 0.033 0.039 0.688
1–2 13 (45) 10 (19) 6 (30)
3 16 (55) 44 (81) 14 (70)
Fibrosis .0.999 .0.999 .0.999
0 0 (0) 0 (0) 1 (5)
1 26 (90) 50 (93) 18 (90)
2 3 (10) 4 (7) 1 (5)
Total score 0.060 .0.999 .0.999
#2 5 (17) 2 (4) 2 (10)
3 8 (28) 8 (15) 4 (20)
4–5 16 (55) 44 (81) 14 (70)
Bold entries indicate significant P values (P, 0.05).
Inflammation (1–3) and fibrosis (0–2) scoring: Higher scores indicate more severe inflammation and fibrosis, respectively (23).
aP value for B2 vs B3s with Bonferroni correction.
bP value for B2 vs B3o with Bonferroni correction.
cP value for B3o vs B3s with Bonferroni correction.
dDoes not include patients without inflammation (n 5 93).
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In conclusion, our study innovatively demonstrated that the
major differentiator between penetrating and stricturing disease
was severity of inflammation because no differences were ob-
served both in fibrosis scores andmost of fibromuscular variables.
We confirmed that pure fibrotic CD may not exist, with in-
flammation and fibromuscular changes overlapping in most pa-
tients irrespective of disease phenotype. Absence of inflammation
was seldom found and only at the proximal ileal surgical margin.
Thus, we herein propose that the designation “fibrostenosing
disease” as a synonym for stricturing disease should be aban-
doned. In fact, CD should again be regarded as a mixture of
inflammatory and fibromuscular changes irrespective of the
phenotype, bearing in mind that higher degrees of inflammation
are characteristic (but not exclusive) of a penetrating behavior.
The focus of future studies should be on identification and
therapeutic targeting of markers of inflammation-dependent and
-independent fibrogenesis in view of preventing progression for
both advanced phenotypes of CD.
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